What Is Livagen? Definition and What Research Reports

Livagen: the short definition

Livagen is a name used in the peptide literature and in research nomenclature for a short synthetic peptide built from four amino acid residues — lysine, glutamic acid, aspartic acid and alanine, usually written as KEDA (Lys-Glu-Asp-Ala). It belongs to a group of very short peptides, often called "short peptide bioregulators" or "peptide bioregulators," that were characterised largely in Russian-language gerontology and biogerontology research and are studied as candidate regulators of gene expression rather than as receptor-binding hormones. Livagen is not an approved drug product in the United States, the European Union or the United Kingdom; where it appears outside of published research it is handled as a research-use-only chemical, and there is no approved labelling, indication or established human dosing framework for it.

What class of molecule is it?

Chemically, Livagen is a tetrapeptide: a chain of four amino acids joined by peptide bonds. That places it at the very small end of the peptide spectrum — far smaller than therapeutic peptides such as insulin (51 residues) or GLP-1 analogues (around 30 residues), and smaller than most peptide hormones. Peptides of two to four residues are the same size class as di- and tripeptides that arise naturally from protein digestion and turnover; researchers have documented that dietary proteins broken down into short peptides can themselves carry measurable biological activity, as in a 2025 food chemistry study that reported hypoglycemic and hypolipidemic effects attributed to short peptides generated from hemp seed protein degradation (PMID 40279904).

Short peptide motifs of this length are also not rare in nature. A 2020 analysis of the human proteome reported that the dipeptide sequence KE — the first two residues of the KEDA sequence — occurs within a large number of human proteins, which the authors used to argue that such fragments may be endogenous signalling remnants rather than purely synthetic constructs (PMID 32246368). Similar reasoning has been applied to viral genomes, where a 2022 study reported that short hydrophobic alpha-helical peptides are encoded in overlapping reading frames of the coronavirus genome (PMID 36014999).

Where the term comes from

The naming convention is what generates confusion around this term. Within the short-peptide bioregulator literature, compounds are typically referred to by their single-letter amino-acid sequence (KEDA, AEDG, KE, EDL, and so on), while trade-style names — Livagen, Epitalon, Vilon, and similar labels — circulate in secondary and non-indexed sources. "Livagen" therefore functions as a colloquial or commercial-style label attached to the KEDA sequence, not as an International Nonproprietary Name or a regulatory designation. Readers comparing sources should expect the same molecule to appear under both naming systems, and should also expect that sequence-based names are what appear in PubMed-indexed titles and abstracts.

How the term is used in peptide research

In practice, "Livagen" appears far more often in general-interest writing than in indexed primary research. The peer-reviewed material available under PubMed indexing for this family of molecules is dominated by other sequences. Because of that, the term is best understood definitionally: it identifies a tetrapeptide within the peptide-bioregulator family, and it signals that any discussion of it sits inside a research programme whose central hypothesis concerns short peptides interacting with DNA and modulating transcription.

That hypothesis has been stated explicitly in the literature. A 2016 review reported that short peptides are capable of regulating gene expression, proposing direct peptide–DNA interaction as one mechanism (PMID 27909961), and a 2014 review in the same tradition framed the relationship between peptides, the genome and aging as its organising question (PMID 25306656). A separate 2020 review examined the delivery routes and reported efficacy considerations for peptide bioregulators, which is relevant background because bioavailability is a recurring question for peptides of this size (PMID 32366071).

What the published literature reports

Livagen-specific controlled human trials are not present in the indexed literature reviewed here, so what follows describes related short peptides and should not be read as evidence about KEDA itself.

For the tetrapeptide AEDG, a 2019 study reported effects on telomere length and on the mitotic index of phytohemagglutinin-stimulated human blood lymphocytes in culture (PMID 31761987). A 2020 paper reported that the same AEDG peptide stimulated gene expression and protein synthesis during neurogenesis in an experimental model, and the authors proposed an epigenetic mechanism for the observation (PMID 32019204).

For the dipeptide KE, a 2023 report described regulation of SIRT1, PARP1 and PARP2 gene expression and protein synthesis in aging human mesenchymal stem cells (PMID 37782636). Related work reported peptide regulation of gene expression and protein synthesis in human bronchial epithelium (PMID 25015171), and a 2016 study examined short peptides in relation to the telomere-length-associated hormone irisin (PMID 26742748). In animal work on a different sequence, a 2017 study reported a nephroprotective effect of the tripeptide EDL in models of acute kidney injury of differing origin (PMID 28744634).

Sequence names encountered alongside Livagen

Livagen safety and tolerability: what studies report

No adverse-event data specific to Livagen appear in the indexed papers reviewed for this entry. The related work described above was conducted predominantly in cell cultures and animal models — for example, cultured human lymphocytes (PMID 31761987) and rodent kidney injury models (PMID 28744634) — and such designs do not generate the kind of systematic safety reporting that regulated human trials produce. The absence of published adverse events in a small non-clinical literature is not evidence of safety; it reflects the fact that the relevant studies were not designed to detect harms. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision or any compound discussed in research.

Limits worth noting when reading about this term

• Sequence versus brand name. Indexed research uses sequence names; "Livagen" is a label, so searches under the trade-style name will surface fewer primary papers than searches under KEDA.
• Evidence tier. The available literature in this family is largely mechanistic and preclinical, and much of it comes from a small number of closely related research groups.
• No transfer between sequences. Findings reported for AEDG, KE or EDL describe those molecules. Extending them to KEDA would be an assumption, not a finding.
• Delivery is an open question. Reviewers have treated delivery and bioavailability of peptide bioregulators as a subject requiring its own analysis (PMID 32366071).
• No approved product. There is no regulatory approval, label or established human dosing for Livagen in major jurisdictions.

References

• Effect of Peptide AEDG on Telomere Length and Mitotic Index of PHA-Stimulated Human Blood Lymphocytes (Bulletin of Experimental Biology and Medicine, 2019)
• KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cells aging (Advances in Gerontology, 2023)
• AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism (Molecules, 2020)
• Peptide KE in Human Proteome (Bulletin of Experimental Biology and Medicine, 2020)
• Short Peptides Regulate Gene Expression (Bulletin of Experimental Biology and Medicine, 2016)
• Peptides, genome, aging (Advances in Gerontology, 2014)
• Peptide regulation of gene expression and protein synthesis in bronchial epithelium (Lung, 2014)
• Short Peptides and Telomere Length Regulator Hormone Irisin (Bulletin of Experimental Biology and Medicine, 2016)
• Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis (Bulletin of Experimental Biology and Medicine, 2017)
• Peptide bioregulators: delivery and efficacy (Vestnik Oftalmologii, 2020)
• Hydrophobic Alpha-Helical Short Peptides in Overlapping Reading Frames of the Coronavirus Genome (Pathogens, 2022)
• Hemp seed protein exerts its hypoglycemic and hypolipidemic effects through degradation into short peptides (Food Chemistry, 2025)